What Has Been the Growth Trajectory for the Typhoid Vi Polysaccharide Vaccine Market in Recent Years?
The typhoid vi polysaccharide vaccine market has seen considerable growth due to a variety of factors.
• In recent times, the market size of the typhoid vi polysaccharide vaccine has witnessed quick expansion. Projected growth indicates an increase in the market size from $5.78 billion in 2024 to $6.77 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 17.1%. The substantial growth during the previous period can be linked to factors including disease prevalence, global health programs, traveler vaccination, immunization initiatives by the government, and vaccine effectiveness and safety.
What Can Be Expected from the Typhoid Vi Polysaccharide Vaccine Market?
The Typhoid Vi Polysaccharide Vaccine market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market for typhoid vi polysaccharide vaccines is predicted to witness accelerated expansion. Projecting a compound annual growth rate (CAGR) of 18.5%.
, it is expected to reach $13.36 billion by 2029. The growth during the forecast period is due to wider immunization initiatives, focus on global health policies, epidemiological monitoring, a surge in travel medicine needs, and environmental and societal influences. The key trends for this duration are likely to be investments in research and development, regulatory backing, epidemiological research, and heightened awareness in public health.
What Are the Critical Driver Fuelling The Typhoid Vi Polysaccharide Vaccine Market's Growth?
The typhoid VI polysaccharide vaccine market is anticipated to experience accelerated growth due to an increase in typhoid cases. Caused by the Salmonella typhi bacteria, typhoid is a potentially deadly infection that typically spreads through contaminated food or beverages. The Typhoid Vi polysaccharide vaccine, which is designed to protect adults and children over the age of 2 from typhoid fever caused by Salmonella enterica serovar Typhi, or S. Typhi, is seeing increasing demand. In fact, in August 2024, the UK Health Security Agency, a government entity based in the UK, reported an uptick in laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland between 2021 and 2022. The report showed S. Typhi cases surging from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, the surge in typhoid cases is spurring the growth of the typhoid Vi polysaccharide vaccine market.
How Is The Typhoid Vi Polysaccharide Vaccine Market segmented?
The typhoid vi polysaccharide vaccine market covered in this report is segmented –
1) By Type: Child, Adult
2) By Route Of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications
Subsegments:
1) By Child: Pediatric Formulations, Age-Specific Dosages
2) By Adult: Standard Adult Formulations, High-Risk Population Formulations
Pre-Book The Typhoid Vi Polysaccharide Vaccine Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Typhoid Vi Polysaccharide Vaccine Market?
The development of strategic alliances is a prominent trend emerging in the typhoid Vi polysaccharide vaccine market. Top-tier companies in the market for typhoid Vi polysaccharide vaccine are engaging in partnerships to solidify their market presence. For example, The International Vaccine Institute, an organization based in South Korea that is dedicated to addressing globally significant infectious diseases like cholera, typhoid, shigella, and salmonella, collaborated with US-based Moderna, a biopharmaceutical enterprise, in July 2022. As a result of this collaboration, the first economical oral cholera vaccine was produced, alongside a cutting-edge typhoid conjugate vaccine.
Who Are the Key Players In The Typhoid Vi Polysaccharide Vaccine Market?
Major companies operating in the typhoid vi polysaccharide vaccine market include:
• Sanofi S.A.
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Pfizer Inc.
• Johnson & Johnson Private Limited
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• Mallinckrodt Pharmaceuticals
• Emergent Biosolutions Inc.
• PT Bio Farma
• Bharat Biotech International Limited
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Bio-Med Pvt. Ltd.
• LG Chem
• SK Chemicals Co. Ltd.
• Crucell Switzerland AG
• Hualan Biological Engineering Inc.
• Indian Immunologicals Limited
What Is The Most Dominant Region In The Typhoid Vi Polysaccharide Vaccine Market?
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
